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Abstract: Tuberculosis (TB) is a chronic infectious disease caused by
Mycobacterium tuberculosis. It is still unknown if TB, like other
infectious diseases contributes a poor prognosis in cirrhotic patients.
The aim of this study was to investigate the impact of TB on the
mortality of cirrhotic patients.
National Health Insurance Database, derived from the Taiwan
National Health Insurance Program, was used to identify 434 cirrhotic
patients with new diagnosis of TB between January 1, 2007 and
December 31, 2007. The comparison group consisted of 4340 selected
cirrhotic patients without TB in the same period by propensity score
matching analysis.
The 30-day, 90-day, 1-year and 3-year mortalities were 10.1%,
24.2%, 43.1%, and 63% in the TB group, and 7.9%, 15.5%, 31.2%, and
53.4% in the non-TB group. After Cox proportional hazard regression
model adjusted by the patients’ gender, age, and comorbid disorders,
the hazard ratios (HR) in cirrhotic patients with TB for 30-day, 30 to
90-day, 90-day to 1-year, and 1 to 3-year mortalities were 1.33 [95%
confidence interval (CI) 0.97–1.83], 1.91 (95% CI 1.45–2.51), 1.46
(95% CI 1.16–1.84), and 1.10 (95% CI 0.88–1.37), compared to the
non-TB group.
In conclusion, TB is a risk factor for the mortality of cirrhotic
patients. The effect focused on the 30-day to 1-year after diagnosis of
TB.
(Medicine 93(28):e295)
Abbreviations: BNHI = National Health Insurance Bureau, CI =Chih-Wei Tseng, M Tsai, PhD,
Tsai, MD
9th Revision, Clinical Modification code, NHIRD = National
Health Insurance Research Database, PSM = propensity score
matching, RFI = renal function impairment, TB = tuberculosis.
INTRODUCTION
C irrhotic patients, regardless of etiology, are prone to haveinfectious diseases due to an acquired immune deficiency,
including antigen-specific and non-specific functions.1,2 There
are 40% hospitalized cirrhotic patients with infection episodes.3
When cirrhotic patients have bacterial infections, they have a
4-fold increase in mortality.4–6
Tuberculosis (TB) is an airborne-transmitted infectious
disease caused by Mycobacterium tuberculosis. TB has been
a leading health problem and remains a major cause of death
worldwide. It is estimated that one-third of the world’s total
population are infected with TB bacilli and there are1.2–1.5
million deaths in 2010.7 Despite a high degree of medical
accessibility, abundant medical resources and the implementa-
tion of Direct Observation Therapy/Short course program,
Taiwan remains a TB endemic area.
More than 10% of TB cases died during the follow-up
period. However, most cases of death during TB treatment in
developed countries are often because of causes other than TB.8,9
In previous reports, the TB patients with chronic liver disease
contributed a higher mortality than those without chronic liver
disease.10,11 Cirrhosis has been proved to be an important prog-
nostic factor in TB patients. However, it is still unknown if TB,
like other bacterial infections has an important impact on the
mortality of cirrhotic patients. In this study, we used nationwide
population-based database to enroll a large population of cirrhotic
patients with and without new diagnosis of TB, The aims of this
study were (1) to investigate the effect of TB on mortality in
cirrhotic patients; (2) to identify the persistence of this effect.
METHODS
Ethical Statement
For studies with human subjects, this study was initiated
after approval by the Institutional Review Board of the Buddhist
Dalin Tzu Chi Hospital in Taiwan (B1010410). Since all
identifying personal information was stripped from the second-
ary files before analysis, the review board waived requirement
for written informed consent from the patients involved.
Database
In 1995, Taiwan started the National Health Insurance
Program. Currently, the National Health Insurance Bureau
(BNHI) covers more than 99% of the Taiwan population. Allll contracted medical institutions must be
for medical payment. In according to
ng the review of the medical services, the
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medical institutions and screens the type, volume, quality
and appropriateness of medical services provided under the
National Health Insurance Program. These medical records are
established as a database, the National Health Insurance
Research Database (NHIRD), which is maintained by BNHI.
The dataset in this study is from this database, which includes all
International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes of the hospitalized patients in
Taiwan. The NHIRD research committee approved the use of
this database to perform this study (agreement number 101516).
The files from NHIRD did not include the patients’ and their
health care providers’ private information.
Study Sample
In this retrospective study, we searched the patients dis-
charged between January 1, 2007 and December 31, 2007 with
diagnostic codes for cirrhosis (ICD-9-CM code 571.5, or 571.2).
Because the etiologies of cirrhosis were very different in young
and adult cirrhotic patients, the patients < 30 years old were
excluded. The patients with biliary cirrhosis (ICD-9-CM code
571.6) also were excluded. The patients with incomplete or
missing basic data in the database were also excluded. In all
cirrhotic patients, the patients with new diagnostic codes for TB
(ICD-9-DM code 010.0–018.96) were enrolled.
In order to regress the effect of TB on the mortality of
cirrhotic patients, we selected the factors related to the mortality
of cirrhotic patients as comorbid medical factors, including
alcoholism (ICD-9-CM codes 291, 303, 305.00–305.03,
571.0–571.3), hepatocellular carcinoma (HCC) (ICD-9-CM
code 155.0), esophageal variceal bleeding (EVB) (ICD-9-CM
code 456.0, 456.20), ascites (ICD-9-CM code 789.5, or pro-
cedure code 54.91), hepatic encephalopathy (HE) (ICD-9-CM
code 572.2), renal function impairment (RFI), and bacterial
infections. The patients with RFI were defined as those with
diagnostic codes related to RFI (ICD-9-CM code 584, 585, 586,
572.4, or other procedure codes relate to renal failure).12
The bacterial infections included pneumonia (ICD-9-CM code
481–487, without 484),13 liver abscess (ICD-9-CM code
572.0), empyema (ICD-9-CM code 510), cellulitis (ICD-9-
CM code 681 or 682), necrotizing fasciitis (ICD-9-CM code
728.86), central nerve system infection (ICD-9-CM code 324 or
Hung et al320), sepsis (ICD-9-CM code 038, 020.0, 790.7, or 112.81),14
infective endocarditis (ICD-9-CM code 421), urinary tract
infection (ICD-9-CM code 590.1, 595.0, 595.9 or 599.0),15
TABLE 1. Demographic Characteristics for Cirrhotic Patients Wit
Non-TB (n¼4340)
Male, n (%) 3501 (80.7)
Age, yrs 61.5 14.2
HCC, n (%) 617 (14.2)
Hepatic encephalopathy, n (%) 238 (5.5)
Ascites, n (%) 852 (19.6)
EVB, n (%) 240 (5.5)
Alcohol-related, n (%) 1307 (30.1)
RFI, n (%) 295 (6.8)
Bacterial infection, n (%) 1141 (26.3)
Propensity score 0.0134 0.006639
EVB¼ esophageal variceal bleeding, HCC¼ hepatocellular carcinoma, R
2 | www.md-journal.combiliary tract infection (ICD-9-CM code 576.1, 575.0, 574.00,
574.01, 574.30, 574.31, 574.60, 574.61, 574.80, 574.81), septic
arthritis, (ICD-9-CM code 711), perianal abscess (ICD-9-CM
code 566), and spontaneous bacterial peritonitis. Spontaneous
bacterial peritonitis was defined as a patient with the ICD-9-CM
diagnosis codes with 567.2, 567.8, or 567.9, and without the
procedure codes for the abdominal surgery.16,17 In addition to
the diagnostic codes mentioned above, we checked all diag-
nostic codes of the enrolled patients to confirm if the patients
have other bacterial infections.
The comparison cohort consisted of the cirrhotic patients
without TB. To avoid the interference of measured confounding
factors, we performed one-to-ten case-control match on pro-
pensity score matching (PSM) that was obtained from logistic
regression of TB on age, alcohol-related, HCC, EVB, Ascites,
HE, RFI, bacterial infection, and gender. Besides, the nearest-
neighbor matching method was used in the propensity model.
Statistical Analysis
The IBM SPSS Statistics package (IBM SPSS Statistics for
Windows, Version 22.0. Armonk, NY: IBM Corp.) was used to
perform the analyses in this study. PSM was performed using
the PSM extension program developed by Felix Thoemmes for
SPSS Statistics in 2011. The Chi-square test or Fisher’s exact
test was used to compare categorical variables. One-way
ANOVA was used to compare continuous variables. In order
to identify risk factors for the mortality, the proportional hazards
Cox regression model was used to control for possible con-
founding factors. We presented hazard ratios (HR) with the 95%
confidence intervals (CI) using a significance level of
P-value< 0.05. The starting point to evaluate of the 30-day,
90-day, 1-year, and 3-year mortalities in the cirrhotic patients
with and without TB was the date of admission in the enrolled
hospitalizations. HR for the mortality was calculated for the
comparison between TB and non-TB groups.
RESULTS
A total of 434 cirrhotic patients with TB were enrolled in
this study, including 347 (80.0%) with pulmonary TB, 4 (0.9%)
with military TB, 72 (16.6%) with extrapulmonary TB, and 11
(2.5%) with both pulmonary and extrapulmonary TB. The
comparison group consisted of 4340 selected cirrhotic patients
Medicine  Volume 93, Number 28, December 2014without TB in the same period by PSM analysis. The mean age
was 61.5 14.2 years in non-TB group and 61.0 14.8 years in
TB group (P¼ 0.895). The demographic characteristics and
h or Without Tuberculosis (n¼4774)
TB (n¼434) P-value
343 (79.0) 0.412
61.0 14.8 0.895
56 (12.9) 0.453
24 (5.5) 0.968
94 (21.7) 0.312
24 (5.5) 1.000
126 (29.0) 0.639
23 (5.3) 0.233
114 (26.3) 0.992
0.0134 0.006648 0.998
FI¼ renal function impairment; TB¼ tuberculosis.
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TABLE 2. Adjusted Hazard Ratios of Risk Factors for the 90-Day Mortality in Cirrhotic Patients After Cox Regression Model
Variable Hazard ratio 95% confidence interval P-value
Age 1.03 1.02–1.03 <0.001
Male 1.32 1.10–1.59 0.003
Alcohol-related 1.03 0.85–1.24 0.797
Hepatic encephalopathy 1.71 1.32–2.22 <0.001
EVB 1.22 0.89–1.67 0.224
Ascites 2.09 1.79–2.44 <0.001
Bacterial infections 1.78 1.53–2.06 <0.001
HCC 1.86 1.55–2.23 <0.001
RFI 2.47 2.01–3.03 <0.001
a, R
Medicine  Volume 93, Number 28, December 2014 Tuberculosis in Cirrhotic Patientcomorbidities of the cirrhotic patients with and without TB are
shown in Table 1. Through PSM, the baseline comorbid factors
did not show statistically differences between TB and non-TB
groups. The 30-day, 90-day, 1-year, and 3-year mortalities were
10.1%, 24.2%, 43.1%, and 63% in the TB group, and 7.9%,
15.5%, 31.2%, and 53.4% in the non-TB group.
In a Cox proportional regression model, adjusted by age,
gender and other comorbid disorders including HCC, EVB,
ascites, alcoholism, RFI, bacterial infection, and HE, the HR of
TB for the 90-day mortalities of cirrhotic patients was 1.62
(95% CI 1.32–1.99, P< 0.001). The HRs of other factors for the
90-day mortalities of cirrhotic patients were listed in Table 2.
RFI, ascites and HE carried higher risk for mortalities in the
cirrhotic patients.
In order to evaluate the early and late effects of TB on
mortality, we calculated the 90-day mortality of the patients
surviving more than 30 days, the 1-year mortality of the patients
surviving more than 90 days, and 3-year mortality of the
patients surviving more than 1 year. The 30 to 90-day, 90-
day to 1-year, and 1 to 3-year mortalities were 15.6%, 24.9%,
and 33.6% in TB group, and 8.3%, 18.5%, and 32.3% in non-TB
group. After Cox proportional regression model adjusted by
age, gender and other comorbid factors, the HRs of TB for 30-
day, 30 to 90-day, 90-day to 1-year, and 1 to 3-year mortalities
in cirrhotic patients were 1.33 (95% CI 0.97–1.83, P¼ 0.073),
1.91 (95% CI 1.45–2.51, P< 0.001), 1.46 (95% CI 1.16–1.84,
P¼ 0.001), and 1.10 (95% CI 0.88–1.37, P¼ 0.408) (Table 3).
We found that the effect of TB on the mortality of cirrhotic
TB 1.62
EVB¼ esophageal variceal bleeding, HCC¼ hepatocellular carcinompatients focused on the 30 day to 1 year after diagnosis of TB.
Figure 1 showed the cumulative survival plot for cirrhotic
patients with and without TB.
Presently, some ideas are developed for prevention of hepato
toxicity induced by anti-TB chemotherapy, including N-acet
ylcysteine,23 silymarin,24 and the herbal formulation o
TABLE 3. Adjusted Hazard Ratios of Tuberculosis for the 30-Day, 30 to 90-Day, 90-Day to 1-Year, 1 to 3-Year Mortalities o
Cirrhotic Patients, Compared to Those Without Tuberculosis
Variable Case number (TB/non TB) Mortality (TB/non TB) Adjusted hazard ratio P-value
30-day 434/4340 10.1/7.9% 1.33 (0.97–1.83) 0.073
30 to 90-day 390/3997 15.6/8.3% 1.91 (1.45–2.51) <0.001
90-day to 1-year 329/3667 24.9/18.5% 1.46 (1.16–1.84) 0.001
1 to 3-year 247/2987 33.6/32.3% 1.10 (0.88–1.37) 0.408
TB¼ tuberculosis.
# 2014 Lippincott Williams & Wilkins www.md-journal.com | 3sDISCUSSION
In 2007, the prevalence of TB was 111 per 100,000
population, and the incidence of TB was 32 per 100,000
population in Taiwan. Totally, 783 of 19,591 TB patients died
in 2007 and the mortality was 4%. Our study showed the
cirrhotic patients with TB had a 10-fold increase in 1-year
mortality. This result was compatible with the data from India,
where the mortality of TB patients with cirrhosis was 80/1000
population, much higher than those for the general population
(0.5–2.3 per 1000 population).18 Our data also showed the
cirrhotic patients without TB had 35.8% of 1-year mortality.
This means that the mortalities of cirrhotic patients with TB
were mostly attributed to cirrhosis itself.
Our study showed that the effect of TB on the mortality of
cirrhotic patients focused on 30 days to 1 year after diagnosis
of TB. The HR was especially higher in the interval of 30 to
90 days. We attributed this result no only to TB itself but also to
the side effect of anti-TB chemotherapy. Previous study showed
cirrhotic patients with TB still responded well to anti-TB
chemotherapy.19 However, the incidence of hepatotoxicity
induced by anti-TB chemotherapy in much higher in cirrhotic
patients.19,20 This kind of hepatotoxicity usually occurs in the
first 2 months of treatment, which can cause significant mor-
bidity and mortality.21,22 This also can cause fewer cirrhotic
patients with TB to complete the expected course of anti-TB
chemotherapy that non-cirrhotic patients with TB.19–22 Accord-
ingly, it is important to reduce treatment-induced hepatotoxicity
for prolonging the survival of cirrhotic patients with TB.
1.32–1.99 <0.001
FI¼ renal function impairment, TB¼ tuberculosis.-
-
f
f
MD-D-14-00418; Total nos of Pages: 5;
MD-D-14-00418
1.0
0.8
0.6
0.4
0.2
0.0
Days
TB
Non-TBC
um
u
la
tiv
e
 s
u
rv
iva
l
0                  200               400                600               800               1000             1200
FIGURE 1. Cumulative survival plot for cirrhotic patients with and without tuberculosis After Cox regression model, the hazard ratios of
to
B is
Hung et al Medicine  Volume 93, Number 28, December 2014Curcuma longa and Tinospora cordifolia.25 However, their
evidences have not been consensus. Early detection and prompt
withdrawal of the offending drug is still the main way to correct
anti-TB chemotherapy-induced hepatotoxicity. Monitoring liv-
er function tests should be more frequently in cirrhotic patients
receiving anti-TB chemotherapy, especially in 30 to 90 days
after treatment.
It is very reasonable that TB has no effect on the mortality
of cirrhotic patients 1 year after treatment. However, it is very
interesting that TB itself has no effect on the first 30-day
mortality of cirrhotic patients after diagnosis of TB. In clinical
presentations, cirrhotic patients with TB have some character-
istics, including low grade temperatures, marked weight loss,
and more extrapulmonary involvement, but they still respond
well to standard anti-TB chemotherapy.19 Previous study
showed that a TB-related mortality rate was only 2.1%, and
the median time from treatment initiation to death was about
23 days.26 Our study also showed about a 2.2% difference of
30-day mortality between TB and non-TB cirrhotic patients
(7.9% vs 10.1%). However, this difference did not show
statistically significant after regression model adjusted by other
comorbid factors. This means that TB-related morality is very
low under anti-TB chemotherapy within first 30 days.
Our study provides evidence that TB increases the
mortality in cirrhotic patients; furthermore, the mortality risk
focused on 30 day to 1-year after diagnosis of TB. Nonetheless,
there were several limitations in our study. First, it was not
possible to identify the Child-Pugh score according to the
diagnostic ICD-9 codes in the database, although the Child-
Pugh score in cirrhotic patients was not proved to be associated
with the outcome in previous studies.27,28 Secondly, the etiol-
ogy for cirrhosis in Taiwan is known mostly to be related to
chronic vial hepatitis, like hepatitis B virus and hepatitis C
virus.29 However, the exact etiology of liver cirrhosis could not
be identified in this population-based study, even though there
were 22.5% cirrhotic patients with diagnostic code of alcohol-
ism. Finally, it was impossible to evaluate the severity and
tuberculosis (TB) for 30-day, 30 to 90-day, 90-day to 1-year, and 1
(1.16–1.84), and 1.10 (0.88–1.37), compared to non-TB group. T
cirrhotic patients.treatment course of TB in this database. Despite these limita-
tions, this study is the first complete nationwide population-
based study for identifying the effect of TB on the mortality of
4 | www.md-journal.comcirrhotic patient. In conclusion, the cirrhotic patients had
increased 30 to 1-year mortality after diagnosis of TB.
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